Andy Skibo

Mr. Skibo has over 40 years of experience in the pharmaceutical industry, with a career focused upon manufacturing operations, quality, process development and capital project development. Most of that career was devoted to biologics operations, starting in 1982 at Genentech, where he was involved in the initial development and scale up of the first large scale, mamallian cell culture processes still in use today. He spent subsequent years at Amgen, his own business, and several large international engineering firms including Foster Wheeler, where he served as President of their Life Sciences Divison. Prior to retiring in April, 2019, Mr. Skibo served for eleven years as MedImmune’s EVP of Operations and Astra Zeneca’s Head of Global Biologics Operations. The latter role included responsibilities for AZ’s biologics and vaccine franchises, including LAIV FluMist/FluEnz. He has served as Chairman of the International Society of Pharmaceutical Engineers, and Chairman of the Global Pharmaceutical Manufacturers Leadership Forum. He has an SB degree in Chemistry, and an MS degree in Chemica Engineering, both from MIT.